Wegovy, Novo Nordisk’s weight loss therapy part of a popular drug class, is now approved for reducing the risk of cardiovascular death, heart attack and stroke in adults who have cardiovascular disease and are either obese or overweight, the FDA said March 8.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
